These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

305 related items for PubMed ID: 26090568

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Evaluation of the appropriateness of dosing, indication and safety of rivaroxaban in a community hospital.
    Tellor KB, Patel S, Armbruster AL, Daly MW.
    J Clin Pharm Ther; 2015 Aug; 40(4):447-51. PubMed ID: 26010016
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Correlation of coagulation markers and 4F-PCC-mediated reversal of rivaroxaban in a rabbit model of acute bleeding.
    Herzog E, Kaspereit F, Krege W, Mueller-Cohrs J, Doerr B, Niebl P, Dickneite G.
    Thromb Res; 2015 Mar; 135(3):554-60. PubMed ID: 25619440
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).
    Patel MR, Hellkamp AS, Lokhnygina Y, Piccini JP, Zhang Z, Mohanty S, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Becker RC, Nessel CC, Berkowitz SD, Califf RM, Fox KA, Mahaffey KW.
    J Am Coll Cardiol; 2013 Feb 12; 61(6):651-8. PubMed ID: 23391196
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Rationale and design of the eXplore the efficacy and safety of once-daily oral riVaroxaban for the prEvention of caRdiovascular events in patients with nonvalvular aTrial fibrillation scheduled for cardioversion trial: A comparison of oral rivaroxaban once daily with dose-adjusted vitamin K antagonists in patients with nonvalvular atrial fibrillation undergoing elective cardioversion.
    Ezekowitz MD, Cappato R, Klein AL, Camm AJ, Ma CS, Le Heuzey JY, Talajic M, Scanavacca MI, Vardas PE, Kirchhof P, Hohnloser SH, Hemmrich M, Lanius V, Meng IL, Wildgoose P, van Eickels M.
    Am Heart J; 2014 May 12; 167(5):646-52. PubMed ID: 24766973
    [Abstract] [Full Text] [Related]

  • 14. Prolongation of prothrombin time in the presence of rivaroxaban: is this the only cause?
    Sagheer S, McRae S.
    Intern Med J; 2017 Feb 12; 47(2):225-227. PubMed ID: 28201865
    [Abstract] [Full Text] [Related]

  • 15. Administration of 4-Factor Prothrombin Complex Concentrate as an Antidote for Intracranial Bleeding in Patients Taking Direct Factor Xa Inhibitors.
    Grandhi R, Newman WC, Zhang X, Harrison G, Moran C, Okonkwo DO, Ducruet AF.
    World Neurosurg; 2015 Dec 12; 84(6):1956-61. PubMed ID: 26341438
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Pulmonary Venous Thromboembolism in an Acutely Ill Medical Patient Receiving Rivaroxaban.
    Saleem A.
    J Coll Physicians Surg Pak; 2017 Sep 12; 27(9):S129-S130. PubMed ID: 28969751
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.